Akers Biosciences Inc. (AKER) financial statements (2020 and earlier)

Company profile

Business Address 201 GROVE RD
THOROFARE, NJ 08086
State of Incorp. NJ
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3550410
Cash and cash equivalents000000
Short-term investments355049
Receivables001112
Inventory, net of allowances, customer advances and progress billings011211
Inventory011211
Prepaid expense0000  
Other current assets    00
Other undisclosed current assets  00  
Total current assets:4783613
Noncurrent Assets
Property, plant and equipment000000
Long-term investments and receivables     1
Due from related parties     1
Intangible assets, net (including goodwill)001112
Intangible assets, net (excluding goodwill)001112
Prepaid expense0     
Other noncurrent assets000000
Other undisclosed noncurrent assets0100  
Total noncurrent assets:112224
TOTAL ASSETS:5895817
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities122122
Accounts payable122122
Due to related parties  00  
Deferred revenue and credits   0
Total current liabilities:122222
Noncurrent Liabilities
Total liabilities:122222
Stockholders' equity
Stockholders' equity attributable to parent4683715
Preferred stock  2   
Common stock122122111101101100
Deferred compensation equity  (0)(0)  
Accumulated other comprehensive income (loss)0(0)  (0)(0)
Accumulated deficit(118)(116)(105)(97)(94)(85)
Total stockholders' equity:4683715
TOTAL LIABILITIES AND EQUITY:5895817

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues223324
Revenue, net3324
Cost of revenue(0)(0)(0)(0)(0) 
Cost of goods and services sold(1)(2)(4)(1)(1) 
Other undisclosed gross profit(1)(1)(2)(1)(1)(1)
Gross profit:101213
Operating expenses(7)(10)(7)(6)(8)(7)
Other undisclosed operating income (loss)1(0)(0)1(3)0
Operating loss:(6)(10)(7)(3)(10)(3)
Nonoperating income (expense)11(1)(0)(0)0
Investment income, nonoperating000(0)(0)0
Loss from continuing operations before equity method investments, income taxes:(5)(9)(7)(3)(10)(3)
Other undisclosed income (loss) from continuing operations before income taxes(2)(2) 00 
Loss from continuing operations before income taxes:(6)(11)(7)(3)(9)(3)
Income tax benefit    0 
Net loss:(6)(11)(7)(3)(9)(3)
Other undisclosed net loss attributable to parent    (0) 
Net loss attributable to parent:(6)(11)(7)(3)(9)(3)
Other undisclosed net income (loss) available to common stockholders, basic132215719(0)
Net income (loss) available to common stockholders, diluted:611739(3)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(6)(11)(7)(3)(9)(3)
Comprehensive loss:(6)(11)(7)(3)(9)(3)
Other undisclosed comprehensive income, net of tax, attributable to parent0     
Comprehensive loss, net of tax, attributable to parent:(6)(11)(7)(3)(9)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: